In this vein, the profiling of 13,942 colon cancers revealed a differential expression of immune-related genes and TME cell infiltration depending on the CDK4/6 expression, hence contributing to the identification of markers useful to assess the response to immune checkpoint inhibitors (ICIs) [108]. The gene discussed is CDK4; the disease is malignant colon neoplasm.